Patents by Inventor Leonid Gorelik
Leonid Gorelik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160380971Abstract: Techniques for informing a user about an agreement including agreement terms and trustworthiness of data source are described herein. In some examples, a processor receives agreement document data while the data is in route to a client device. A system receives network sources and content data of the agreement document. The network sources are to be processed by the processor with traffic analytics, and the content data is to be processed with text analytics. The output of these analytics is used to generate an agreement risk event for delivery to the client device with the original agreement document data.Type: ApplicationFiled: May 6, 2016Publication date: December 29, 2016Inventors: Leonid Gorelik, Abraham Hochmann, Josemina M. Magdalen, Alexander Pyasik, Yifat Yulevich
-
Publication number: 20160381046Abstract: Techniques for informing a user about an agreement including agreement terms and trustworthiness of data source are described herein. In some examples, a processor receives agreement document data While the data is in route to a client device. A system receives network sources and content data of the agreement document. The network sources are to be processed by the processor with traffic analytics, and the content data is to be processed with text analytics. The output of these analytics is used to generate an agreement risk event for delivery to the client device with the original agreement document data.Type: ApplicationFiled: June 23, 2015Publication date: December 29, 2016Inventors: Leonid Gorelik, Abraham Hochmann, Josemina M. Magdalen, Alexander Pyasik, Yifat Yulevich
-
Publication number: 20160187337Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.Type: ApplicationFiled: March 8, 2016Publication date: June 30, 2016Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
-
Publication number: 20160151390Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immuno-compromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: December 3, 2015Publication date: June 2, 2016Applicant: Biogen MA Inc.Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Patent number: 9316641Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.Type: GrantFiled: January 11, 2011Date of Patent: April 19, 2016Assignee: BIOGEN MA INC.Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
-
Patent number: 9233107Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: GrantFiled: September 13, 2008Date of Patent: January 12, 2016Assignee: Biogen MA Inc.Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Publication number: 20150242639Abstract: Examples of techniques for detecting and preventing sensitive information leaks are described herein. In one example, a method for detection of sensitive information leaks includes computing, via a processor, a set of rules that identify sensitive information, and sending, via the processor, the set of rules to a dispatcher application using a protocol. The method can also include detecting, via the processor, that at least one data block of the transmitted data matches the set of rules, and executing, via the processor, a corrective action in response to detecting that at least one of the transmitted data blocks matches the set of rules.Type: ApplicationFiled: November 18, 2014Publication date: August 27, 2015Inventors: Guy Galil, Leonid Gorelik, Alexander Pyasik, Oded Sofer, Yifat Yulevich
-
Publication number: 20150242633Abstract: Examples of techniques for detecting and preventing sensitive information leaks are described herein. In one example, a method for detection of sensitive information leaks comprises computing, via a processor, a set of rules that identify sensitive information, and sending, via the processor, the set of rules to a dispatcher application using a protocol. The method can also include detecting, via the processor, that at least one data block of the transmitted data matches the set of rules, and executing, via the processor, a corrective action in response to detecting that at least one of the transmitted data blocks matches the set of rules.Type: ApplicationFiled: February 26, 2014Publication date: August 27, 2015Applicant: International Business Machines CorporationInventors: Guy Galil, Leonid Gorelik, Alexander Pyasik, Oded Sofer, Yifat Yulevich
-
Publication number: 20150219651Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.Type: ApplicationFiled: January 22, 2015Publication date: August 6, 2015Applicant: Biogen Idec MA Inc.Inventors: Leonid Gorelik, Alexey Lugovskoy
-
Publication number: 20140213470Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.Type: ApplicationFiled: November 21, 2013Publication date: July 31, 2014Applicants: GENENTECH, INC., BIOGEN IDEC MA INC.Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
-
Publication number: 20140199291Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 17, 2014Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Patent number: 8617545Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.Type: GrantFiled: October 12, 2006Date of Patent: December 31, 2013Assignees: Biogen Idec MA Inc., Genentech, Inc.Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
-
Publication number: 20130183289Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 18, 2013Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Publication number: 20130101985Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.Type: ApplicationFiled: February 5, 2010Publication date: April 25, 2013Applicant: BIOGEN IDEC MA INC.Inventors: Leonid Gorelik, Alexey Lugovskoy
-
Publication number: 20130022961Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.Type: ApplicationFiled: January 11, 2011Publication date: January 24, 2013Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
-
Publication number: 20120258443Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.Type: ApplicationFiled: February 5, 2010Publication date: October 11, 2012Applicant: BIOGEN IDEC MA INC.Inventors: Leonid Gorelik, Alexey Lugovskoy
-
Publication number: 20100330066Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.Type: ApplicationFiled: October 12, 2006Publication date: December 30, 2010Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
-
Publication number: 20100279316Abstract: The present invention relates to antibodies that bind phosphorylated forms of IRAK4, methods of using such antibodies to detect IRAK4 biological activity, and methods for the detection, diagnosis, and prognostication of pathological conditions related to IRAK4 biological activity. ERAK4 is one member of a small family of highly conserved cytoplasmic signal transduction proteins characterized by the presence of an N-terminal “death domain” and a C-terminal serine-threonine kinase domain. IRAK4 functions in cytoplasmic signal transduction pathways by interacting with membrane spanning proteins which play, inter alia, critical roles in vertebrate immune system function.Type: ApplicationFiled: January 9, 2008Publication date: November 4, 2010Inventors: Leonid Gorelik, Darren P. Baker, Catherine A. Hession, Karyn Van De Mark, Robert M. Arduini, Craig Wildes